Welcome to our dedicated page for Sutro Biopharma SEC filings (Ticker: STRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with antibody-drug conjugate data, clinical trial tables, and collaboration footnotes can feel like decoding another language. Sutro Biopharma’s disclosures are no exception—they weave cell-free manufacturing costs, milestone payments, and pipeline updates into hundreds of pages. That complexity is exactly why this page exists.
Stock Titan’s AI-powered summaries turn dense documents into plain-English insights. Whether you need the Sutro Biopharma annual report 10-K simplified for cash-runway projections or a quick take on a Sutro Biopharma quarterly earnings report 10-Q filing, we surface what matters: R&D spend, collaboration revenue, and clinical milestone timing. Real-time alerts track every Sutro Biopharma Form 4 insider transactions real-time, helping you gauge executive confidence long before the market reacts.
Looking for something specific? Start with these common questions we answer directly on this page:
- “Where can I find Sutro Biopharma insider trading Form 4 transactions?”—all Forms 3, 4, and 5 are indexed with AI tags on option grants and share sales.
- “How do I read the latest 8-K?”—each Sutro Biopharma 8-K material events explained note links straight to trial results, FDA designations, or partnership announcements.
- “What’s new in the proxy?”—our breakdown of the Sutro Biopharma proxy statement executive compensation highlights pay tied to pipeline milestones.
Because filings never stop, neither do we. Expect comprehensive coverage of every submission—10-K, 10-Q, S-1, 8-K, and more—updated the moment EDGAR releases them. Need deeper context? Click any section for Sutro Biopharma earnings report filing analysis or tap the chatbot for understanding Sutro Biopharma SEC documents with AI. No spreadsheets to build, no jargon to untangle—just the data that drives decisions.
Monitor Sutro Biopharma executive stock transactions Form 4, compare quarter-over-quarter R&D trends, or export pipeline metrics for your model. Complex science, clear filings—delivered in seconds.
Sutro Biopharma (STRO) filed its Q3 2025 report, showing revenue of $9.7 million, up from $8.5 million a year ago. For the nine months, revenue reached $90.8 million versus $47.2 million, driven by collaboration activity including accelerated recognition tied to changes in partner programs. Q3 net loss was $56.9 million compared to $48.8 million, reflecting restructuring charges of $9.6 million in the quarter and $49.0 million year-to-date.
Unrestricted cash, cash equivalents and marketable securities totaled $167.6 million as of September 30, 2025, and management expects this to fund operations for at least 12 months after filing. Total assets were $209.7 million; the company reported a stockholders’ deficit of $87.3 million, largely due to an accumulated deficit of $931.2 million and a deferred royalty obligation of $209.9 million. Deferred revenue declined to $12.7 million from $82.3 million as obligations were satisfied. Sutro is prioritizing three preclinical ADC programs, exiting its internal GMP facility by year-end, and has announced workforce reductions that cumulatively approximate two-thirds. The company received a Nasdaq minimum bid price notice with a compliance period through December 17, 2025.
Sutro Biopharma (STRO)Exhibit 99.1. The company states the information under Item 2.02, including Exhibit 99.1, is being furnished and not filed under the Exchange Act, and is not subject to Section 18 liabilities nor incorporated by reference except as expressly stated.
Sutro Biopharma (STRO): Insider transaction reported. A company officer (Chief Administrative Officer & General Counsel) purchased 12,504 shares of Common Stock on 10/15/2025 at $0.7992 per share, according to a Form 4 filing.
Following the transaction, the officer directly beneficially owns 71,737 shares. The total includes 2,500 shares acquired through the company’s Employee Stock Purchase Plan, as noted in the filing’s explanation.
Sutro Biopharma (STRO) reported an insider share purchase. A director bought 50,000 shares of common stock on 10/15/2025 at a price of $0.799 per share, according to a Form 4 filing. Following the transaction, the reporting person beneficially owns 50,000 shares, held directly.
Sutro Biopharma (STRO) disclosed an insider stock purchase by its Chief Executive Officer and Director, Jane Chung. On 10/15/2025, the reporting person purchased 12,500 shares of common stock at $0.8009 per share (transaction code P). Following this transaction, the reporting person beneficially owned 122,850 shares, held in direct ownership.
No derivative securities were reported in this filing.
Sutro Biopharma (STRO) reported an insider purchase on Form 4. CFO Gregory K. Chow bought 19,750 shares of common stock on 10/15/2025 with transaction code P (purchase). The weighted average price was $0.81, with individual trades executed between $0.8099 and $0.8100. Following the transaction, he beneficially owned 19,750 shares, held directly.
Sutro Biopharma (STRO) reported an insider purchase by its Chief Scientific Officer, Hans-Peter Gerber. On October 15, 2025, he bought 17,000 shares of common stock at a weighted average price of $0.8004 per share in open-market transactions. Following the trade, he beneficially owned 71,832 shares, held directly.
The filing notes the shares were acquired through multiple executions within a price range of $0.7932 to $0.8015, and provides to interested parties the breakdown of shares purchased at each price upon request.
Hans-Peter Gerber, Chief Scientific Officer of Sutro Biopharma, acquired equity and vested awards on 09/18/2025. The Form 4 shows 37,500 restricted stock units (RSUs) were recorded as acquired and will settle into common stock; each RSU converts to one share on settlement. Following the transactions, Mr. Gerber beneficially owned 75,000 shares of common stock. Additionally, the issuer withheld 13,417 shares
David Pauling, Chief Administrative Officer and General Counsel of Sutro BioPharma, Inc. (STRO), amended his Form 3 to correct the number of shares he beneficially owns. The filing reports 56,733 shares of common stock held directly. The amendment notes the original Form 3 filed on April 8, 2025 misstated the total and is otherwise unchanged. The event date requiring the statement is 04/04/2025, and the amended Form 3/A is signed by Mr. Pauling on 09/12/2025.
FAQ
What is the current stock price of Sutro Biopharma (STRO)?
What is the market cap of Sutro Biopharma (STRO)?
